Skip to main content
SpringerLink
Log in

Intravenous iron has several benefits in end-stage renal failure

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sunder-Plassman G, Hörl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf 1997; 17(4): 241–50

    Article  Google Scholar 

  2. Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment. BMJ 1992; 304: 225–6

    Article  PubMed  CAS  Google Scholar 

  3. Koch KM, Patyna WD, Shaldon S, et al. Anaemia of the regular haemodialysis patient and its treatment. Nephron 1974; 12: 405–19

    Article  PubMed  CAS  Google Scholar 

  4. Drücke TB, Bárány P, Cazzola M, et al. Management of iron deficiency in renal anaemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48: 1–8

    Google Scholar 

  5. Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694–9

    Article  PubMed  CAS  Google Scholar 

  6. Fishbane S, Frei Gl, Maesaka J, et al. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1993; 22Suppl. 1: 3–12

    Google Scholar 

  7. Sepandj F, Jindal K, West M, et al. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 1996; 11: 319–22

    Article  PubMed  CAS  Google Scholar 

  8. Kaufman J, Reda D, Goldfarb D, et al. Diagnosis and treatment of iron deficiency in patients on maintenance recombinant human erythropoietin (rHuEPO) [abstract]. J Am Soc Nephrol 1996; 7: 1450

    Google Scholar 

  9. Taylor JE, Peat N, Porter C, et al. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1079–83

    Article  PubMed  CAS  Google Scholar 

  10. Zanen AL, Adriansen HJ, van Bommel EFH, et al. Oversaturation of transferrin after ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820–4

    Article  PubMed  CAS  Google Scholar 

  11. Sunder-Plassman G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070–6

    Google Scholar 

  12. Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72: 234–8

    Article  Google Scholar 

  13. Sunder-Plassman G, Hörl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1997; 11: 1797–802

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Intravenous iron has several benefits in end-stage renal failure. Drugs Ther. Perspect 11, 9–11 (1998). https://doi.org/10.2165/00042310-199811110-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811110-00003

Keywords

Search

Navigation